Search
Search Results
-
The diversity and clinical implications of genetic variants influencing clopidogrel bioactivation and response in the Emirati population
BackgroundClopidogrel is a widely prescribed prodrug that requires activation via specific pharmacogenes to exert its anti-platelet function. Genetic...
-
Pleiotropic effects of clopidogrel
Clopidogrel is a widely prescribed prodrug with anti-thrombotic activity through irreversible inhibition of the P2Y 12 receptor on platelets. It is...
-
Analysis of the effect of CYP2C19 gene properties on the anti-platelet aggregation of clopidogrel after carotid artery stenting under network pharmacology
Antiplatelet therapy is an important factor influencing the postterm patency rate of carotid artery stenting (CAS). Clopidogrel is a platelet...
-
Transcriptome-wide map of N6-methyladenosine (m6A) profiling in coronary artery disease (CAD) with clopidogrel resistance
BackgroundClopidogrel resistance profoundly increases the risk of major cardiovascular events in coronary artery disease (CAD) patients. Here, we...
-
The Complement System and C4b-Binding Protein: A Focus on the Promise of C4BPα as a Biomarker to Predict Clopidogrel Resistance
The complement system plays a dual role in the body, either as a first-line defense barrier when balanced between activation and inhibition or as a...
-
Ticagrelor versus clopidogrel in reducing inflammatory cell infiltration of thrombus aspirated in patients with ST-elevation myocardial infarction
BackgroundTicagrelor provides more rapid, potent, and consistent anti-platelet efficacy than clopidogrel. This randomized trial aimed to evaluate the...
-
Clinical non-effectiveness of clopidogrel use for peripheral artery disease in patients with CYP2C19 polymorphisms: a systematic review
PurposeTo conduct a systematic review to identify studies that assessed the association between CYP2C19 polymorphisms and clinical outcomes in...
-
Influence of daily versus alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrel
BackgroundVonoprazan, a potassium-competitive acid blocker, inhibits gastric acid secretion and attenuates the antiplatelet function of clopidogrel...
-
Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease
PurposeDual antiplatelet therapy with aspirin and clopidogrel is commonly used for coronary artery disease (CAD) patients undergoing percutaneous...
-
Impact of Genetic Variation on Drug Response
Pharmacogenomics investigates the influence of genetics on drug response, with the ultimate aim of giving patients the right drug at the right dose...
-
The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention
BackgroundAcute coronary syndrome (ACS) carries a high mortality in Uygur populations. Percutaneous coronary intervention (PCI) is a safe treatment...
-
The need of a multicomponent guiding approach to personalize clopidogrel treatment
Patients bearing polymorphisms termed CYP2C19 loss of function (LoF) alleles and ABCB1 -C3435T may do not properly respond to standard dosage of...
-
CYP2C19 Loss-of-Function Associated with First-Time Ischemic Stroke in Non-surgical Asymptomatic Carotid Artery Stenosis During Clopidogrel Therapy
This study measures effect of CYP2C19 genotype on ischemic stroke risk during clopidogrel therapy for asymptomatic, extracranial carotid stenosis...
-
Pretreatment of Indobufen and Aspirin and their Combinations with Clopidogrel or Ticagrelor Alleviates Inflammasome Mediated Pyroptosis Via Inhibiting NF-κB/NLRP3 Pathway in Ischemic Stroke
Increasing studies showed that several anti-platelet drugs turned out to be a promising strategy for inflammatory response. In this study, we...
-
Evidence on the Impact of Pharmacogenetics to Treat and Manage Cardiovascular Diseases
Cardiovascular diseases are the leading cause of morbidity and mortality worldwide. Effective medications for the treatment of cardiovascular...
-
Monitoring of Antiplatelet Therapy
In the late 1990s, the antithrombotic antiplatelet agent, clopidogrel, a P2Y12 inhibitor, was introduced. Around the same time, there was an increase...
-
Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study
BackgroundCardiovascular diseases and especially Acute Coronary Syndrome (ACS) constitute a major health issue impacting millions of patients...
-
Age-dependent association of CYP2C19 polymorphisms with clinical outcome of clopidogrel therapy in minor stroke patients with large-artery atherosclerosis
PurposePrevious studies on the association between CYP2C19 polymorphisms and therapeutic outcome of clopidogrel in stroke patients are inconclusive....
-
A Genomic Study of the Japanese Population Focusing on the Glucocorticoid Receptor Interactome Highlights Distinct Genetic Characteristics Associated with Stress Response
All living organisms have been programmed to maintain a complex inner equilibrium called homeostasis, despite numerous adversities during their...
-
Genetic variability in stroke patients: CYP2C19 polymorphisms unraveled
ObjectiveTo study the distribution characteristics of CYP2C19 polymorphisms in patients suffering from stroke in Han Chinese patients.
...